Pre-made Diridavumab benchmark antibody ( Whole mAb, anti-Influenza A HA2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Diridavumab biosimilar, Whole Mab: Anti-Influenza A HA2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Diridavumab (CR6261) (INN) is a monoclonal antibody designed for the treatment of influenza A.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-147-1mg	1mg	3090
GMP-Bios-ab-147-10mg	10mg	Inquiry
GMP-Bios-ab-147-100mg	100mg	Inquiry
GMP-Bios-ab-147-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Diridavumab biosimilar, Whole Mab: Anti-Influenza A HA2 therapeutic antibody
INN Name	Diridavumab
Target	Influenza A HA2
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Lambda
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Active
100% SI Structure	3gbn:HL/3gbm:HL:IM/5c0s:HL
99% SI Structure	None
95-98% SI Structure	4evn:AB:CD:IJ:OP:KL:EF:GH:MN
Year Proposed	2014
Year Recommended	2015
Companies	National Institute of Allergy and Infectious Diseases;Crucell
Conditions Approved	na
Conditions Active	Influenza A virus (H1N1) infections
Conditions Discontinued	na
Development Tech	na